lipoprotein

Rosuvastatin (ZD4522) is an inhibitor of HMG-CoA reductase (HMGCR) (IC50=11 nM), selective and competitive. Rosuvastatin has hypolipidemic and antiatherosclerotic effects.

Rosuvastatin calcium (ZD4522) , a selective and competitive inhibitor of hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, has antilipidemic activity.

Torcetrapib (CP-529414) is a cholesteryl ester transfer protein (CETP) inhibitor designed to reduce the heterotypic transfer of cholesteryl ester from HDL to LDL and/or VLDL. It failed in phase III trials due to an excess of deaths.

1. Pseudoprotodioscin has moderate cytotoxicity.

Ibrolipim (NO-1886) attenuates high glucose-induced endothelial dysfunction in cultured human umbilical vein endothelial cells via PI3K/Akt pathway.

Oxidized low density lipoprotein (Human) (Human ox-LDL) is the oxidized form of human low-density lipoprotein (LDL), used to study lipid transport and atherosclerosis. Human ox-LDL stimulates endothelial cell activation and adhesion molecule production, inhibits eNOS activity and NO generation, and activates NLRP3 inflammasomes in macrophages.

Lipoprotein lipase (LPL) is an enzyme, mainly involved in lipid metabolism, that hydrolyzes triglycerides in lipoproteins.LPL can be a target for obesity/diabetes-related cardiovascular diseases and has an important role in lowering triglyceride levels and improving cardiovascular.

Low-density lipoprotein (human) is one of the five main lipoproteins responsible for transporting cholesterol to various tissues such as the adrenal glands, gonads, muscle, and adipose tissue.

Oxidized low density lipoprotein (mouse) is a modified form of low-density lipoprotein (LDL). It induces atherosclerosis (AS) by promoting endothelial dysfunction and accelerating the growth and migration of vascular smooth muscle cells (VSMCs).

High density lipoprotein (HDL) (human) is a functional lipoprotein capable of binding to receptors such as scavenger receptor B1 (SR-B1), ABCA1, and ABCG1. It facilitates the removal of excess cholesterol from peripheral tissues through reverse cholesterol transport (RCT), transferring it to the liver for metabolism. Additionally, it activates endothelial nitric oxide synthase (eNOS) to produce nitric oxide (NO), offering antioxidant, anti-inflammatory, and vascular endothelial protection. High density lipoprotein (human) is a potential candidate for cardiovascular disease research, including atherosclerosis.

Muvalaplin (LY3473329) is an orally active lipoprotein (a) [Lp(a)] reagent that inhibits Lp(a) formation by blocking apo(a)-apo B100 interactions.

ApolipoproteinKV domain (67-77) is an 11-amino-acid peptide isolated from the KV domain of human apolipoprotein a (ApoA), known for its anti-angiogenic and anti-tumor activities. It targets the angiogenesis c-Src/ERK pathway by blocking activation signals received from vascular endothelial growth factor (VEGF). ApolipoproteinKV domain (67-77) is applicable in cancer research.

HumanapolipoproteinAIV is a plasma protein synthesized primarily in the enterocytes of the small intestine during fat absorption. It serves as a major circulating apolipoprotein and plays a role in dietary fat absorption, triglyceride transport, and the reverse transport of cholesterol.

Lp(a)-IN-5 (Compound A) is an orally active inhibitor of lipoprotein (a) [Lp(a)]. It effectively inhibits the assembly of Apo(a) and ApoB proteins, with an IC50 value of 0.41 nM. Lp(a)-IN-5 shows potential for research into diseases associated with elevated plasma Lp(a) levels, such as cardiovascular diseases.

Lp(a)-IN-7 (example 1) is an inhibitor of lipoprotein (a) [Lp(a)] formation, exhibiting an IC50 of 2.51 nM in media containing apolipoprotein B (apoB) and apolipoprotein (a). This compound is applicable in cardiovascular disease research.

APL180 (L-4F) is an apolipoprotein A-I mimetic peptide that enhances the anti-inflammatory activity of high-density lipoprotein (HDL). It is applicable for cardiovascular disease research.

APP-018 (D-4F) is an 18 D-amino acid peptide that mimics apolipoprotein A-I (apoA-I). It enhances the anti-inflammatory properties of high-density lipoprotein (HDL) and is applicable in cardiovascular disease research.

APL180 TFA (L-4F) is an apolipoprotein A-I mimetic peptide that enhances the anti-inflammatory functions of High-density lipoprotein. It participates in cardiovascular protection by modulating lipid metabolism and inflammatory responses, and is commonly used in studies of cardiovascular disease mechanisms.

BLT-1 is a scavenger receptor BI (SR-BI)inhibitor.

EZ-482 is an apolipoprotein (apoE) ligand that binds to the C-terminal domain of apoE3 and apoE4 through a unique N-terminal allosteric effect, useful in Alzheimer's disease research.

APOL1-IN-2 (Compound 467) acts as an inhibitor of apolipoprotein L1 (APOL1). It effectively reduces HEK293 cell death induced by APOL1 G2/G1, with EC50 values of 4.74 nM and 14.3 nM, respectively. Additionally, APOL1-IN-2 decreases the mortality of trypanosomes triggered by APOL1 G2/G1/G0, with EC50 values of 2.24, 6.03, and 3.72 nM, respectively.

APOL1-IN-3 is an APOL1 inhibitor used for kidney disease research.

Plozasiran, previously called ARO-APOC3, is a first-in-class investigational RNA interference (RNAi) therapeutic that is specifically designed to actively suppress hepatic production of apolipoprotein C-III (APOC3), a critical structural and functional component of triglyceride-rich lipoproteins (TRLs) and a central regulator of systemic triglyceride metabolism, thereby addressing dyslipidemia at the level of gene expression through targeted post-transcriptional silencing mechanisms.

Volanesorsenscramble negative control is the negative control form of Volanesorsen with the sequence: CAUGUTCUTCUGCATGUCAU. Volanesorsen (ISIS 304801) is an antisense oligonucleotide inhibitor targeting apolipoprotein CIII (apo-CIII) mRNA, effectively reducing triglyceride levels and improving insulin resistance.